Researchers tested a new experimental drug called XRF-1021 that may help people with high uric acid levels in their blood. High uric acid can damage kidneys over time and cause gout. The drug works by helping the kidneys get rid of more uric acid through urine, rather than letting it build up in the body. In studies with animals, the drug successfully lowered uric acid levels and protected kidney function. The researchers also found the drug appeared safe, even at high doses. While these results are encouraging, the drug still needs to be tested in humans before doctors can prescribe it.
The Quick Take
- What they studied: Whether a new experimental drug could lower high uric acid levels in the blood by helping kidneys remove more uric acid
- Who participated: Laboratory studies using human kidney cells, rats, quails, and mice with high uric acid levels or kidney damage
- Key finding: The drug XRF-1021 successfully lowered uric acid levels in all animal models tested and appeared to protect kidney function without causing obvious side effects
- What it means for you: This research suggests a potential new treatment option for people with high uric acid may eventually become available, but it’s still years away from being used in patients. More testing in humans is needed first.
The Research Details
Scientists tested a new drug called XRF-1021 in multiple ways to understand how it works. First, they used laboratory tests to see if the drug affected how the body makes or breaks down uric acid. Then they used human kidney cells and genetically modified rats to study how the drug affects the proteins that transport uric acid in kidneys. Finally, they tested the drug in three different animal models with high uric acid levels—some with acute (sudden) high uric acid and others with chronic (long-lasting) high uric acid and kidney damage. They also tested how safe the drug was by giving high doses to animals and watching for side effects over time.
This research approach is important because it shows exactly how the drug works before testing it in animals. By understanding the mechanism first, researchers can predict whether it will be safe and effective. Testing in multiple animal models with different types of high uric acid problems helps show that the drug works in various situations, making it more likely to help different patients.
The study used multiple complementary approaches (lab tests, cell studies, and animal models) which strengthens confidence in the findings. The researchers tested the drug’s safety thoroughly, including measuring how much of the drug stays in the body and testing for long-term toxicity. However, this is still early-stage research—animal studies don’t always translate to human results. The study was published in a peer-reviewed journal, meaning other scientists reviewed it for quality.
What the Results Show
XRF-1021 lowered uric acid levels in all animal models tested. The drug worked by blocking two specific proteins in the kidneys (called URAT1 and GLUT9) that normally reabsorb uric acid back into the bloodstream. By blocking these proteins, the drug allowed more uric acid to be removed through urine instead of staying in the blood. The drug showed dose-dependent effects, meaning higher doses produced stronger results. In animals with kidney damage from high uric acid, the drug not only lowered uric acid but also appeared to protect the kidneys from further damage.
The drug did not affect other important kidney transport proteins (OAT3, OAT4, and ABCG2), which is good because these proteins help remove other waste products and medications from the body. In fact, the drug appeared to increase activity of OAT3 and another protein called NPT4, which could help remove other harmful substances. The drug did not work by affecting how the body produces uric acid or breaks it down—it worked purely by increasing excretion. Safety testing showed the drug had high lethal dose values (2345.4 mg/kg in males and 1078.9 mg/kg in females), suggesting a wide safety margin, and no obvious toxicity was observed after long-term dosing in animals.
This research builds on the researchers’ previous work showing that XRF-1021 had anti-fibrosis activity (meaning it could prevent kidney scarring). This study explains the mechanism behind the uric acid-lowering effect and confirms it works through a different pathway than existing uric acid-lowering drugs. Most current medications either block uric acid production or activate uric acid breakdown, so a drug that increases uric acid excretion represents a novel approach that could potentially be combined with existing treatments.
This study was conducted entirely in laboratory cells and animals—it has not been tested in humans yet. Animal results don’t always translate to humans due to differences in metabolism and physiology. The study doesn’t provide information about potential side effects in humans or how well humans would tolerate the drug. The exact sample sizes for some experiments aren’t clearly specified in the abstract. Long-term effects in humans are unknown. The drug’s effectiveness in different patient populations (different ages, genders, or with other health conditions) hasn’t been evaluated.
The Bottom Line
Based on this research, XRF-1021 appears to be a promising candidate for treating high uric acid, but it is NOT yet ready for human use. The evidence is strong for its effectiveness in animal models (confidence: moderate to high for animal studies), but human clinical trials are needed before any recommendations can be made for patients. Anyone with high uric acid should continue using their current prescribed treatments and discuss any new treatment options with their doctor.
This research is most relevant to people with chronic high uric acid levels, especially those with gout or kidney disease related to uric acid buildup. It may also interest people who don’t tolerate current uric acid medications well. People should NOT try to obtain this drug outside of clinical trials, as it is still experimental. This research is also important for pharmaceutical companies and researchers developing new treatments for high uric acid.
If this drug moves forward to human trials, it typically takes 5-10 years before a new medication becomes available to patients. Phase 1 trials (safety in small groups) would come first, followed by Phase 2 (effectiveness in larger groups) and Phase 3 (comparison to existing treatments). Even if all trials are successful, regulatory approval is required before prescription use.
Want to Apply This Research?
- Users could track their serum uric acid levels (from blood tests) every 3 months and record the date and value in the app. They could also note any gout attacks or kidney-related symptoms to see if patterns emerge with uric acid levels.
- Users interested in managing high uric acid could use the app to track foods high in purines (like red meat, organ meats, and certain seafood) and monitor how dietary changes affect their uric acid levels over time. They could set reminders to take current medications as prescribed and log any side effects.
- Create a dashboard showing uric acid trends over months and years, with annotations for medication changes, dietary modifications, and symptom occurrences. Users could share this data with their doctor to optimize their current treatment plan while staying informed about emerging therapies like XRF-1021.
This research describes an experimental drug (XRF-1021) that has NOT been approved for human use and is not available for treatment. The study was conducted in laboratory cells and animals only. Results in animals do not guarantee the same results in humans. Anyone with high uric acid levels should continue working with their healthcare provider and using prescribed medications. Do not attempt to obtain or use XRF-1021 outside of authorized clinical trials. This article is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before making changes to your treatment plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.